Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 8/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3633468 | 0.96 | HSD11B1 (0.68) | HSD11B1ALDH1A1EPHX2SLC6A4SLC6A3 | |
| SCHEMBL7177946 | 0.93 | ALDH1A1 (0.61) | HSD11B1ALDH1A1EPHX2SLC6A4SLC6A3 | |
| SCHEMBL5363393 | 0.85 | ALDH1A1 (0.66) | HSD11B1ALDH1A1L3MBTL1TSHR | |
| SCHEMBL21214447 | 0.85 | ALDH1A1 (0.55) | HSD11B1ALDH1A1EPHX2SLC6A4SLC6A3 | |
| SCHEMBL12836587 | 0.84 | SLC6A4 (0.54) | HSD11B1ALDH1A1EPHX2SLC6A4SLC6A3 | |
| SCHEMBL11104354 | 0.84 | SLC6A4 (0.50) | HSD11B1ALDH1A1EPHX2SLC6A4SLC6A3 | |
| SCHEMBL625584 | 0.83 | HSD11B1 (0.64) | HSD11B1ALDH1A1EPHX2SLC6A4SLC6A3 | |
| SCHEMBL16565616 | 0.82 | ALDH1A1 (0.56) | HSD11B1ALDH1A1EPHX2 | |
| SCHEMBL627571 | 0.82 | HSD11B1 (0.90) | HSD11B1SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL14525408 | 0.82 | HSD11B1 (0.63) | HSD11B1ALDH1A1EPHX2L3MBTL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9156788-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2015-10-13 | — | — | US | disclosed |
| EP-2603490-A1 | NOVEL TRPV3 MODULATORS | AbbVie Inc. (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20130150409-A1 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-06-13 | — | — | US | disclosed |
| CN-103140476-A | Novel trpv3 modulators | ABBOTT LAB | 2013-06-05 | — | — | CN | disclosed |
| WO-2012019315-A1 | NOVEL TRPV3 MODULATORS | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | WO | disclosed |
| US-7816375-B2 | Ligands for monoamine receptors and transporters, and methods of use thereof | SEPRACOR INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816375-B2 | Ligands for monoamine receptors and transporters, and methods of use thereof | SEPRACOR INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20090258901-A1 | LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF | AQUILA BRIAN M | 2009-10-15 | — | — | US | disclosed |
| US-20090258901-A1 | LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF | AQUILA BRIAN M | 2009-10-15 | — | — | US | disclosed |
| US-7517892-B2 | Ligands for monoamine receptors and transporters, and methods of use thereof | SEPRACOR INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517892-B2 | Ligands for monoamine receptors and transporters, and methods of use thereof | SEPRACOR INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-7294637-B2 | Method of treating addiction or dependence using a ligand for a monamine receptor or transporter | SEPRACOR, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| US-7294637-B2 | Method of treating addiction or dependence using a ligand for a monamine receptor or transporter | SEPRACOR, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| US-4629727-A | ANTIDEPRESSANTS | THE BOOTS COMPANY PLC (GB) | 1986-12-16 | — | — | US | disclosed |
| EP-0111994-B1 | (1-ARYLCYCLOBUTYL) ALKYLAMINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS THERAPEUTIC AGENTS | The Boots Company PLC (GB) | 1986-02-26 | — | — | EP | disclosed |
| EP-0111994-A1 | (1-Arylcyclobutyl) alkylamine derivatives, their preparation and their use as therapeutic agents | The Boots Company PLC (GB) | 1984-06-27 | — | — | EP | disclosed |
| US-4443449-A | Arylcyclobutylalkylamines and anti-depression composition and methods using same | THE BOOTS COMPANY LIMITED (GB) | 1984-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150409-A1 | NOVEL TRPV3 MODULATORS | TRPV3, TRPV4, TRPV5 | HSD11B1 2616/4885ALDH1A1 2560/4885EPHX2 2519/4885 |
| US-20090258901-A1 | LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF | SLC6A2, OPRL1, SLC18A2 | HSD11B1 721/4885ALDH1A1 873/4885EPHX2 1367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.